Watch This
  • Trending
  • Explore

The Coyle Family Story - Living with Hereditary ATTR (hATTR) amyloidosis

This video was created for audiences in the UK & Ireland. Cousins James and Pat recall the story of their family’s experience of hATTR amyloidosis, including genetic testing and their hopes for the future of those diagnosed with the disease. NP IRL 00012

Join Today
Sophia's experience living with hATTR amyloidosis
▶︎

Sophia's experience living with hATTR amyloidosis

Alnylam & RNAi Therapeutics: Making our Medicines
▶︎

Alnylam & RNAi Therapeutics: Making our Medicines

Chen (Brazil) – Living with hATTR Amyloidosis
▶︎

Chen (Brazil) – Living with hATTR Amyloidosis

Alnylam Act - No Charge, Third Party Genetic Testing & Counseling
▶︎

Alnylam Act - No Charge, Third Party Genetic Testing & Counseling

Alnylam & RNAi Therapeutics: Silencing Disease. Amplifying Life.
▶︎

Alnylam & RNAi Therapeutics: Silencing Disease. Amplifying Life.

Alnylam & RNAi Therapeutics: Making our Medicines
▶︎

Alnylam & RNAi Therapeutics: Making our Medicines

Marc – Living with Wild-Type ATTR Amyloidosis with Cardiomyopathy
▶︎

Marc – Living with Wild-Type ATTR Amyloidosis with Cardiomyopathy

Ben, Lebt Mit AHP
▶︎

Ben, Lebt Mit AHP

Physiopathologie de la PHA
▶︎

Physiopathologie de la PHA

Alnylam's siRELIS(TM) Enzymatic Ligation Platform
▶︎

Alnylam's siRELIS(TM) Enzymatic Ligation Platform

Stephanie, Atteinte de PHA
▶︎

Stephanie, Atteinte de PHA

Alnylam Challengers: Improving Access to Healthcare in Boston by Investing in Care Navigators
▶︎

Alnylam Challengers: Improving Access to Healthcare in Boston by Investing in Care Navigators

A Message from Alnylam CEO Yvonne Greenstreet - Reflecting on 2025 and Looking forward to 2026
▶︎

A Message from Alnylam CEO Yvonne Greenstreet - Reflecting on 2025 and Looking forward to 2026

RNAi, a promising platform for drug development
▶︎

RNAi, a promising platform for drug development

Alnylam Announces $250 Million Expansion of U.S. RNAi Therapeutics Manufacturing Facility
▶︎

Alnylam Announces $250 Million Expansion of U.S. RNAi Therapeutics Manufacturing Facility

AboutContactPrivacyTerms
Made with ❤️ by Abdo